[Federal Register Volume 85, Number 95 (Friday, May 15, 2020)]
[Notices]
[Pages 29457-29458]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10408]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-20-19BHC]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled National Evaluation of the DP18-1815 
Cooperative Agreement Program: Category A, Diabetes Management and Type 
2 Diabetes Prevention to the Office of Management and Budget (OMB) for 
review and approval. CDC previously published a ``Proposed Data 
Collection Submitted for Public Comment and Recommendations'' notice on 
July 5, 2019, to obtain comments from the public and affected agencies. 
CDC did not receive comments related to the previous notice. This 
notice serves to allow an additional 30 days for public and affected 
agency comments.
    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570. Comments and recommendations for the proposed 
information collection should be sent within 30 days of publication of 
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular 
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct 
written comments and/or suggestions regarding the items contained in 
this notice to the Attention: CDC Desk Officer, Office of Management 
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 
395-5806. Provide written comments within 30 days of notice 
publication.

Proposed Project

    National Evaluation of the DP18-1815 Cooperative Agreement Program: 
Category A, Diabetes Management and Type 2 Diabetes Prevention--New--
National Center for Chronic Disease Prevention and Health Promotion 
(NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    The Centers for Disease Control and Prevention (CDC) Division of 
Diabetes Translation (DDT) and Division for Heart Disease and Stroke 
Prevention (DHDSP) are submitting this new information collection 
request (ICR) for an evaluation of the recently launched five-year 
Cooperative Agreement program CDC-RFA-DP18-1815PPHF18: Improving the 
Health of Americans Through Prevention and Management of Diabetes and 
Heart Disease and Stroke, hereafter referred to as ``1815''. This 
cooperative agreement funds all 50 State Health Departments and the 
Washington, DC health department (hereafter referred to as ``HD 
recipients'') to support investments in implementing evidence-based 
strategies to prevent and manage cardiovascular disease (CVD) and 
diabetes in high-burden populations/communities within each state and 
the District of Columbia. High burden populations/communities are those 
affected disproportionately by high blood pressure, high blood 
cholesterol, diabetes, or prediabetes due to socioeconomic or other 
characteristics, including access to care, poor quality of care, or low 
income. The 1815 program is a collaboration between DDT and DHDSP and 
is structured into two program categories aligning with each

[[Page 29458]]

Division: Category A focuses on diabetes management and type 2 diabetes 
prevention; Category B focuses on CVD prevention and management. This 
information request package focuses on data collection activities for 
the Category A diabetes assessment.
    This cooperative agreement is a substantial investment of federal 
funds. DDT and DHDSP are responsible for the stewardship of these 
funds, and they must be able to demonstrate the types of interventions 
being implemented and what is being accomplished through the use of 
these funds. Thus, throughout the five-year cooperative agreement 
period, CDC will work with HD recipients to track the implementation of 
the cooperative agreement strategies and evaluate program processes and 
outcomes. In order to collect this information for Category A, CDC has 
designed two overarching components: (1) Category A rapid evaluation of 
DSMES and National DPP partner sites and (2) Category A recipient-led 
evaluations. Each component consists of data collection mechanisms and 
tools that are designed to capture the most relevant information needed 
to inform the evaluation effort while placing minimum burden on 
respondents. Respondents will include HD recipients, as well as select 
HD recipient partner sites, which are organizations that HD recipients 
are partnering with in the implementation of the 1815 strategies.
    The evaluation of cooperative agreement strategies and activities 
conducted by DDT will determine the efficiency, effectiveness, impact 
and sustainability of 1815-funded strategies in the promotion, 
prevention, and management of diabetes and heart disease and help 
identify promising practices that can be replicated and scaled to 
better improve health outcomes. In addition, evaluation plays a 
critical role in organizational learning, program planning, decision-
making, and measurement of the 1815 strategies. As an action-oriented 
process, the evaluation will serve to identify programs that have 
positive outcomes, identify those that may need additional technical 
assistance support, and highlight the specific activities that make the 
biggest contribution to improving diabetes and cardiovascular disease 
prevention and management efforts. Without collection of new evaluative 
data, CDC will not be able to capture critical information needed to 
continuously improve programmatic efforts and clearly demonstrate the 
use of federal funds.
    OMB approval is requested for three years. Participation is 
required for cooperative agreement awardees and voluntary for partner 
sites. The total estimated annualized burden hours are 1,084.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                                      Average
                                                                     Number of       Number of      burden per
         Type of respondent                   Form name             respondents    responses per   response  (in
                                                                                    respondent        hours)
----------------------------------------------------------------------------------------------------------------
Health Department (1815 Recipient).  Evaluation and Performance               17               1               8
                                      Measurement Plan (EPMP).
                                     Recipient-Led Evaluation                 51               1               8
                                      Reporting Template.
                                     DSMES Partner Site-Level                 17               1             0.5
                                      Rapid Evaluation Rapid
                                      Evaluation Form.
                                     National DPP Partner Site-               17               1             0.5
                                      Level Rapid Evaluation
                                      Nomination Form.
DSMES Partner Site.................  DSMES Partner Site-Level                340               1             0.5
                                      Rapid Evaluation Survey
                                      Questionnaire.
                                     Program Coordinator                      14               1               2
                                      Interview Guide.
                                     Professional Team Member                 28               1               2
                                      Interview Guide.
                                     Paraprofessional Team                    28               1               2
                                      Member Interview Guide.
National DPP Partner Site..........  National DPP Partner Site-              340               1             0.5
                                      Level Rapid Evaluation
                                      Survey Questionnaire.
                                     Program Coordinator                      14               1               1
                                      Interview Guide.
                                     Lifestyle Coach Interview                28               1               1
                                      Guide.
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2020-10408 Filed 5-14-20; 8:45 am]
BILLING CODE 4163-18-P